Semaglutide for heart health in schizophrenia with metabolic syndrome
Part of Hormones & metabolism, Mental health clinical trials.
This trial tests whether semaglutide, a drug used for diabetes and weight loss, can improve heart-related health in people with schizophrenia who also have metabolic syndrome (a cluster of conditions like high blood pressure, high blood sugar, and excess belly fat). If it works, it could lower the risk of heart disease and stroke.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of schizophrenia and have been taking a second-generation antipsychotic (like risperidone, olanzapine, or quetiapine) for more than 6 months.
- You meet the criteria for metabolic syndrome, which means you have at least three of these: large waistline, high blood pressure, high blood sugar, high triglycerides, or low HDL cholesterol.
- You are over 25 years old, any gender.
- You are not taking clozapine, aripiprazole, or more than one antipsychotic at the same time.
- You do not have a history of severe head injury or another major psychiatric, medical, or neurological disorder.
- You are not pregnant or breastfeeding, and you agree to use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether the drug semaglutide can help people with heart failure who are overweight. It aims to see if the drug improves heart function and symptoms.
This study tests if a medication called semaglutide can help people with obesity lose weight by changing the bacteria in their gut. You may be able to join if you have obesity, have tried to lose weight before, and are generally healthy.
This study tests a medication called semaglutide (which helps with weight loss) in people with obesity who have struggled to lose weight before. It will see how much weight participants can lose while taking the drug.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This trial tests whether semaglutide (a medicine that helps control blood sugar and weight) can improve outcomes for people with type 1 diabetes who have a higher body weight. It may help if you have had type 1 diabetes for at least 3 years and have a BMI of 30 or more, or 27 or more with a related health problem.
This trial tests if semaglutide, a medicine used for diabetes and weight loss, can help people with both psoriasis and obesity. You may qualify if you have moderate to severe psoriasis, a high body weight, and are of Chinese descent.
Hear when a new Metabolic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.